|Day Low/High||39.16 / 39.64|
|52 Wk Low/High||34.32 / 46.47|
U.S. corporate earnings have come in largely ahead of analysts' forecasts in the first two weeks of the reporting season, according to data from Refinitiv, but the rate at which companies are beating estimates continues to slip below both near and longer-term averages, suggesting the fading impact of tax cuts, and concerns about slowing global growth, could dampen profits over the first half of the year.
Jim Cramer's plan for getting through the heart of earnings season next week.
Merck and Pfizer have been laggards so far in 2019. Technical warnings occurred on Dec. 4 when both set multiyear highs and both received downgrades.
Johnson & Johnson posted stronger-than-expected fourth quarter earnings Tuesday and forecast a modest increase in full year sales for 2019 that would take its top line past $81 billion.
Big pharma is shaping up to be a consolidating category in 2019.
Jim Cramer talks about how this market is taking its cues from the positives, and shrugging off the negatives.
One of pharma's biggest CEO's talks M&A action on the exchange.
Do we have to run for the hills? Not necessarily.
Pfizer Inc. (NYSE: PFE) announced today that the US Food and Drug Administration (FDA) accepted for filing the company's New Drug Applications (NDAs) for tafamidis for the treatment of transthyretin amyloid cardiomyopathy (ATTR-CM).
My stated reason for being in Pfizer all along has been price stability and income.
This is the kind of reversal that happens in a bull market.
Nasdaq is an American stock market and the home of stocks that make up major indexes like the Nasdaq Composite and Nasdaq 100.
We're out in San Francisco this week covering the amazing innovations that so many companies reveal at this annual conference.
BMY agreed to acquire CELG for $74 billion in cash and stock.
Pfizer Inc. (NYSE: PFE) announced today the initiation of a Phase 2b/3 clinical trial for its oral JAK3 inhibitor, PF-06651600, for the treatment of patients with moderate to severe alopecia areata, a chronic autoimmune skin disease that causes hair loss...
The health care sector may a good place to weather this storm. Here is why and how to play it.
Take upbeat outlooks for equities with a grain of salt, and try these sectors to stay safe.
Pfizer Inc. invites investors and the general public to listen to a webcast of a discussion with Albert Bourla, Chief Operating Officer, and Mikael Dolsten, President, Worldwide Research and Development, at the 37 th Annual J.
Jim Cramer explains the art and science of technical analysis.
A study of analyst recommendations at the major brokerages shows that Pfizer Inc is the #24 broker pick, on average, out of the 30 stocks making up the Dow Jones Industrial Average, according to ETF Channel. Within the broader S&P 500, when components were ranked in terms of analyst favorites, PFE claims the #355 spot.
Pfizer Inc. invites investors and the general public to listen to a webcast of a discussion with Albert Bourla, Chief Operating Officer, at the Goldman Sachs 11 th Annual Healthcare CEOs Unscripted: A View from the Top on Thursday, January 3, 2019 at...
ABBV offers an ideal mix of growth, value and income.
DARMSTADT, Germany, and NEW YORK, December 21, 2018 /PRNewswire/ -- Not intended for UK-based media Merck KGaA, Darmstadt, Germany, and Pfizer Inc.
Pfizer Inc. (NYSE:PFE) announced today that the Phase 2b trial STRIVE ( STaphylococcus aureus SuRgical Inpatient Vaccine Efficacy) evaluating the company's investigational Staphylococcus aureus ( S.
TOKYO and NEW YORK, Dec. 20, 2018 /PRNewswire/ -- Astellas Pharma Inc.
Stocks plunged Wednesday afternoon following the Federal Reserve's decision to raise rates by a quarter point.
U.S. stock futures rise Wednesday as investors prep for an announcement from the Federal Reserve on interest rates; Micron tumbles after a weak second-quarter sales forecast; Glaxo and Pfizer combine their consumer health businesses; FedEx slumps after lowering its outlook.
GlaxoSmithKline shares surged to the top of the European market Wednesday after the drugmaker said it would combine its consumer health division with U.S. rival Pfizer's to create a new division with $13 billion in annual sales.
Pfizer Inc. (NYSE: PFE) and GlaxoSmithKline plc (NYSE:GSK) today announced they have entered into an agreement to create a premier global consumer healthcare company with robust iconic brands.
TheStreet’s Fundamentals of Investing Course will teach you the keys to making the right decisions in any market.
TheStreet’s Personal Finance Essentials Course will teach you money management basics and investing strategies to help you avoid major financial pitfalls.
TheStreet Courses offers dedicated classes designed to improve your investing skills, stock market knowledge and money management capabilities.
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.
A confirmation email has been sent to the address provided during registration. Please click on the appropriate link to confirm your email address.